Treatment of myelodysplastic syndromes with 5-azacytidine
Treatment of myelodysplastic syndromes with 5-azacytidine
复制标题
DOI：
10.1016/s0145-2126(02)00028-0
复制
发表时间：
2002-10-01
影响因子：
2.7
通讯作者：
Evans, C
中科院分区：
文献类型：
--
作者：
Gryn, J;Zeigler, ZR;Evans, C
贫血和/或血小板减少的骨髓增生异常综合征（MDS）患者接受5-a/酰基苷（5-AZA）治疗，剂量为75mg /m(2) /天SQ × 7天。每28天重复一次。48例接受至少一个周期5-AZA治疗的患者可评估反应。血液毒性轻微，包括血小板减少和白细胞减少，髓外毒性罕见，包括肺炎、关节痛、腹泻和注射部位刺激。46例输血依赖患者中有18例（39%）不再依赖输血。中位缓解持续时间为7个月，其中3例持续时间超过2年。法英分级（FAB）和国际评分系统（ISS）不能预测5-AZA的疗效。然而，在5-AZA的初始周期中，白细胞（WBC）的减少与更高的应答率相关(C) 2002 Elsevier Science Ltd.。版权所有。
Patients with myelodysplastic syndromes (MDS) who were anemic and/or thrombocytopenic were treated with 5-a/acytidine (5-AZA) at a dose of 75 mg-/m(2) per day SQ x 7 days. This cycle was repeated every 28 days. Forty-eight patients who received at least one cycle of 5-AZA were evaluable for response. Hematological toxicity was mild and consisted of thrombocytopenia and leukopenia Extramedullary toxicity was uncommon and consisted of pneumonia, arthralgia, diarrhea, and injection site irritation. Eighteen of the 46 transfusion dependent patients became transfusion independent (39%). Median duration of response was 7 months with three patients continuing beyond 2 years. French Anglo British (FAB) classification and the International Scoring System (ISS) did not predict response to 5-AZA. However, a decrease in the white blood cells (WBC) during the initial cycle of 5-AZA correlated with a higher response rate (C) 2002 Elsevier Science Ltd. All rights reserved.